Aachen, Germany and Utrecht, the Netherlands – February 25, 2019
MILabs B.V. is pleased to announce that the Institute of Experimental Molecular Imaging (ExMI) at the RWTH Aachen University has chosen the MILabs high resolution CT to further enhance its world-leading molecular imaging research. Together with the new MILabs optical tomography system, this unrivaled hybrid OI/CT system enables 3D/4D quantitative imaging in deep-tissues guided by high-contrast X-ray CT images, obtained at extremely low radiation doses.
According to Univ.-Prof. Dr. med. Fabian Kiessling, director of the ExMI Institute, “The low-dose CT and tomographic optical imaging capabilities of the system support our work in the field of nanomedicines and theranostics, and their application to diagnose and treat oncological and cardiovascular diseases. We are focused on research of new devices, contrast agents, therapeutics and postprocessing tools. Using high-contrast CT to guide 3D optical imaging is critical for these applications and we are glad that MILabs has embraced and adopted our Imalytics CT-segmentation and fluorescence reconstruction approaches developed by Dr. Felix Gremse, one of the group leaders within our institute”
MILabs’ founder and CEO and Delft University Prof. Dr. Frederik Beekman confirms: “We are pleased with the application tests performed by ExMI to validate our unique 3D/4D Optical/CT imaging capabilities. Optical/CT further extends the application range of our award-winning VECTor molecular imaging platform from bench-to-clinic. This scalable integrated platform now includes PET, SPECT, quantitative 3D autoradiography, radiotherapy imaging, luminescence, fluorescence and X-ray CT.”
About ExMI-RWTH Aachen:
RWTH Aachen University or Rheinisch-Westfälische Technische Hochschule Aachen is a research university located in Aachen, North Rhine-Westphalia, Germany. With more than 42,000 students, it is the largest technical university in Germany. RWTH Aachen collaborates with the Helmholtz Association and various Helmholtz centers on numerous projects, including Experimental Molecular Imaging (ExMI). The ExMI Institute focuses on the development of novel contrast agents, imaging techniques and therapeutic approaches to characterize and treat cancer, cardiovascular and inflammatory disorders. For more information, visit http://exmi.rwth-aachen.de
About MILabs B.V.:
The company has a history of providing a continuum of innovations to expand the applications of its multimodality imaging solutions used for the development of new diagnostic solutions and therapies. With its latest adaptive preclinical platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate PET, SPECT, Optical and CT imaging in a single integrated and user-friendly system. Awarded the Commercial Innovation of the Year 2018 at the Molecular Imaging Congress, this platform is globally recognized for being able to deliver the highest quality molecular, functional and anatomical images. For more information, visit: www.milabs.com or contact MILabs at firstname.lastname@example.org